Myriad Genetics, MYGN
Morgan Stanley lowered the firm’s price target on Myriad Genetics (MYGN) to $16 from $21 and keeps an Equal Weight rating on the shares after ...
Short sellers have been increasing their bets, with short interest now accounting for 6.1% of the stock's available float.
UnitedHealthcare will stop covering Myriad Genetics' GeneSight test in 2025, impacting $45 million in revenue. Myriad ...
Myriad Genetics (NASDAQ:MYGN – Get Free Report) had its price objective dropped by investment analysts at UBS Group from $18.00 to $16.00 in a note issued to investors on Tuesday,Benzinga reports. The ...
Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, today announced a ...
Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic tests. It operates through the Diagnostics and Other segments. The Diagnostics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results